David Jenkins, CEO of Catheter Precision (VTAK), commented: “We are extremely excited about our results on all fronts: increasing sales, strong clinical data, and execution of strategic transactions with a goal of increasing the future value of Catheter Precision. We are seeing increased awareness and desire for our products, both here in the US, and now, with the CE Mark for the LockeT in Europe, internationally as well. The team is energized with our progress, and we are looking forward to our results in the coming quarters.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Upcoming Stock Splits This Week (August 11 to August 15) – Stay Invested
- Catheter Precision: Heart Hospital completes 200 ablation procedures with VIVO
- Catheter Precision Approves Reverse Stock Split Plan
- Catheter Precision announces order from Centre Hospitalier Universitaire
- Catheter Precision forms new joint venture with Chelak iECG called Kardionav